Evidence map›Paper›PMID 25756396›Full record

Observational studyBritish journal of cancer2015

The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.

C E Hooper, I D Lyburn, J Searle, M Darby, T Hall, D Hall, A Morley, P White, N M Rahman, E De Winton and 10 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. PET-CT-guidedThe European respiratory journal · 2024
    Trial
  7. Prognostic value of SUVTranslational lung cancer research · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

C E Hooper1] Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK [2] North Bristol Lung Centre, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK.
I D LyburnCobalt Health, Thirlestaine Road, Cheltenham GL53 7AS, UK.
J SearleCobalt Health, Thirlestaine Road, Cheltenham GL53 7AS, UK.
M DarbyDepartment of Radiology, Southmead Hopsital, North Bristol NHS Trust, Bristol BS10 5NB, UK.
T HallDepartment of Radiology, Royal United Bath Hospital, Bath BA1 3NG, UK.
D HallCobalt Health, Thirlestaine Road, Cheltenham GL53 7AS, UK.
A MorleyNorth Bristol Lung Centre, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK.
P WhiteApplied Statistics Group, University of West of England (UWE), Bristol BS16 1QY, UK.
N M RahmanOxford Respiratory Clinical Trial Unit (Funded by the NIHR Biomedical Research Centre), Churchill Hospital, Oxford OX3 7LJ, UK.
E De WintonDepartment of Oncology, Royal United Hospital Bath BA1 3NG, UK.
A CliveAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK.
V MasaniDepartment of Respiratory Medicine, Royal United Hospital Bath BA1 3NG, UK.
D T ArnoldAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK.
A DangoorBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK.
S GuglaniDepartment of Oncology, Cheltenham General Hospital, Cheltenham GL53 7AN, UK.
P JankowskaDepartment of Oncology, Musgrove Park Hospital, Severn Drive, Taunton TA1 5DA, UK.
S A LowndesDepartment of Oncology, Great Western Hospital, Swindon SN3 6BB, UK.
J E HarveyNorth Bristol Lung Centre, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK.
J P BraybrookeBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK.
N A Maskell1] Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK [2] North Bristol Lung Centre, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK.

Funding

Marie Curie MCCC-RP-14-A17178
6 · The paper itself

Abstract

backgroundRobust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care.

methodsConsecutive patients with MPM who were considered fit for first-line chemotherapy were prospectively recruited. Patients of similar performance status opting for best supportive care were included as a comparator group. Baseline and interval CT, PET-CT and serum markers (mesothelin, fibulin-3 and neutrophil-lymphocyte ratio (NLR)) were obtained, and patients followed up for a minimum 12 months.

findingsSeventy-three patients were recruited (58 chemotherapy/15 comparator arm). Baseline TGV (total glycolytic volume on PET-CT) was an independent predictor of worse overall survival (OS) (P=0.001). Change in interval TGV(baseline/after two cycles of chemotherapy) did not predict OS or chemotherapy response on CT. Baseline NLR<4 was an independent predictor of better OS (median survival 453 (IQR 272-576) days vs NLR⩾4, 257 (IQR 147-490), P=0.002). Although baseline serum mesothelin did not predict OS, a falling level at 8 weeks significantly predicted longer time to progression (TTP) (P<0.001).

interpretationNeutrophil-lymphocyte ratio and baseline TGV predict prognosis in malignant pleural mesothelioma (MPM), but PET-CT is unhelpful in monitoring chemotherapy response. Serum mesothelin is a useful early treatment response marker when measured serially during chemotherapy and may have a role in evaluating patients' treatment response.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorLung NeoplasmsMesotheliomaAgedAged, 80 and overCarboplatinCisplatinCohort StudiesFemaleGlutamatesGuanineHumansLymphocytesMaleMesothelioma, MalignantBiomarkers, TumorCarboplatinCisplatinGlutamatesGuaninePemetrexed

Identifiers

PMID25756396
PMCPMC4385956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.